A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Balinatunfib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SPECIFI-CD
- Sponsors Sanofi
Most Recent Events
- 06 Jan 2025 Planned End Date changed from 22 May 2029 to 23 May 2029.
- 06 Jan 2025 Planned primary completion date changed from 16 Mar 2025 to 21 Jul 2027.
- 06 Jan 2025 Status changed from not yet recruiting to recruiting.